These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 665797)

  • 1. Effect of haloperidol and apomorphine treatment on dopamine receptors in pituitary and striatum.
    Friend WC; Brown GM; Jawahir G; Lee T; Seeman P
    Am J Psychiatry; 1978 Jul; 135(7):839-41. PubMed ID: 665797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
    Nomura Y; Komori T; Okuda S; Segawa T
    Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):25-30. PubMed ID: 485682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
    Rupniak NM; Hall MD; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 Aug; 34(15):2755-63. PubMed ID: 4040370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of haloperidol and apomorphine on the K+-depolarized overflow of [3H] dopamine from rat striatal slices.
    Miller JC; Friedhoff AJ
    Biochem Pharmacol; 1979 Mar; 28(5):688-90. PubMed ID: 444255
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity.
    Creese I; Burt DR; Snyder SH
    Science; 1977 Aug; 197(4303):596-8. PubMed ID: 877576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.
    Bannon MJ; Bunney EB; Zigun JR; Skirboll LR; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jun; 312(2):161-5. PubMed ID: 6772975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic treatment with haloperidol modifies the sensitivity of autoreceptors that modulate dopamine release in rat striatum.
    Yamada S; Yokoo H; Nishi S
    Eur J Pharmacol; 1993 Feb; 232(1):1-6. PubMed ID: 8458389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.
    Burt DR; Creese I; Snyder SH
    Science; 1977 Apr; 196(4287):326-8. PubMed ID: 847477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine receptors in the central nervous system.
    Seeman P; Tedesco JL; Lee T; Chau-Wong M; Muller P; Bowles J; Whitaker PM; McManus C; Tittler M; Weinreich P; Friend WC; Brown GM
    Fed Proc; 1978 Feb; 37(2):131-6. PubMed ID: 414936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presynaptic dopamine receptors in striatal nerve endings: absence of haloperidol-induced supersensitivity.
    Raiteri M; Cerrito F; Casazza G; Levi G
    Adv Biochem Psychopharmacol; 1980; 24():37-43. PubMed ID: 7405669
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of amantadine HCl on haloperidol-induced striatal dopamine neuron hypersensitivity.
    Allen RM; Flemenbaum A
    Biol Psychiatry; 1979 Jun; 14(3):541-4. PubMed ID: 573144
    [No Abstract]   [Full Text] [Related]  

  • 13. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation.
    Carvey PM; Hitri A; Goetz CG; Tanner CM; Klawans HL
    Life Sci; 1988; 42(22):2207-15. PubMed ID: 3374255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
    Allen RM; Lane JD; Brauchi JT
    Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 16. High- and low-affinity states of striatal D2 receptors are not affected by 6-hydroxydopamine or chronic haloperidol treatment.
    MacKenzie RG; Zigmond MJ
    J Neurochem; 1984 Nov; 43(5):1310-8. PubMed ID: 6208330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subchronic buspirone, mesulergine, and ICS 205-930 lack effects on D1 and D2 dopamine binding in the rat striatum during chronic haloperidol treatment.
    Young KA; Zavodny R; Hicks PB
    J Neural Transm Gen Sect; 1991; 86(3):223-8. PubMed ID: 1837997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
    Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
    Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary.
    Jaber M; Tison F; Fournier MC; Bloch B
    Brain Res Mol Brain Res; 1994 Apr; 23(1-2):14-20. PubMed ID: 7518029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dopaminergic agonists and antagonists on [3H]apomorphine binding to striatal membranes: sulpiride lack of interactions with positive cooperative [3H]apomorphine binding.
    Fujita N; Saito K; Hirata A; Iwatsubo K; Noguchi Y; Yoshida H
    Brain Res; 1980 Oct; 199(2):335-42. PubMed ID: 7417787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.